| | Vemurafenib | Dabrafenib | Dacarbazine |
| Base case adverse event probabilities by drug [4, 6] | | | | | Vomiting, nausea, Grades 1, 2 | 0.0023 | 0.0009 | 0.0106 | Vomiting, nausea, Grades 3, 4 | 0.0010 | 0 | 0.0007 | Diarrhea, Grades 1, 2 | 0.0230 | 0 | 0.0006 | Diarrhea, Grades 3, 4 | 0.0005 | 0 | 0.0001 | Hyperkeratosis, Grades 1, 2 | 0.0172 | 0.0113 | 0 | Hyperkeratosis, Grades 3, 4 | 0.0010 | 0.0009 | 0 | Skin papilloma, Grades 1, 2 | 0.0169 | 0 | 0 | Skin papilloma, Grades 3, 4 | 0 | 0 | 0 | Squamous cell carcinoma, Grades 1, 2 | 0 | 0.0018 | 0 | Squamous cell carcinoma, Grades 3, 4 | 0.0105 | 0.0036 | 0 | Keratoacanthoma, Grades 1, 2 | 0.0051 | 0 | 0 | Keratoacanthoma, Grades 3, 4 | 0 | 0 | 0 | Neutropenia, Grades 1, 2 | 0.0002 | 0 | 0.0019 | Neutropenia, Grades 3, 4 | 0.0002 | 0.0004 | 0.0086 | PPE, Grades 1, 2 | 0 | 0.0055 | 0 | PPE, Grades 3, 4 | 0 | 0.0018 | 0 | Leukopenia, Grades 1, 2 | 0 | 0 | 0.0013 | Leukopenia, Grades 3, 4 | 0 | 0 | 0.0007 | Thrombocytopenia, Grades 1, 2 | 0 | 0 | 0 | Thrombocytopenia, Grades 3, 4 | 0 | 0 | 0.0020 |
| | Base case value | Sensitivity analysis | Distribution | | Lower value | Upper value |
| Drug-specific utility values for each health state including side effects | | | | | Stable disease, dacarbazine | 0.69 | 0 | 1 | Beta | Progression, dacarbazine | 0.45 | 0 | 1 | Beta | Stable disease, dabrafenib | 0.79 | 0 | 1 | Beta | Progression, dabrafenib | 0.52 | 0 | 1 | Beta | Stable disease, vemurafenib | 0.73 | 0 | 1 | Beta | Progression, vemurafenib | 0.49 | 0 | 1 | Beta |
| Monthly drug costs (2013 USD) | | | | | Dacarbazine cost per month, assuming one cycle per month and including administration and prophylactic antiemetic treatment costs [12–14] | $988.86 | $678.29 | $1356.85 | Gamma
| Dabrafenib monthly cost [6, 13] | $7569.60 | $5677.20 | $9462.00 | Gamma | Vemurafenib monthly cost [4, 13] | $10807.40 | $8105.55 | $13509.25 | Gamma |
| Toxicity management costs per month on treatment | | | | | Hyperkeratosis, Grades 1, 2 [13, 15, 16] | $126.66 | $114.26 | $424.95 | Gamma | Hyperkeratosis, Grades 3, 4 [13, 15, 16] | $1082.84 | $1070.84 | $1706.93 | Gamma | Squamous cell carcinoma [15, 17] | $1595 | $1128 | $3408 | Gamma | Nausea, vomiting BRAF inhibitor, Grades 1, 2 [12, 13] | $274.58 | $274.58 | $419.54 | Gamma | Nausea, vomiting BRAF inhibitor, Grades 3, 4 [12–14] | $6855.76 | $4480.05 | $8009.39 | Gamma | Diarrhea, Grades 1, 2 [13, 18] | $5.81 | $5.81 | $45.89 | Gamma | Diarrhea, Grades 3, 4 [13–15, 18] | $7404.11 | $3550.28 | $7845 | Gamma | Keratoacanthoma, Grades 1, 2 [6, 13, 15] | $113.67 | $66.72 | $181.31 | Gamma | Skin papilloma, Grades 2, 3 [15] | $73 | $61 | $97 | Gamma | PPE [13, 15, 19, 20] | $113.67 | $113.67 | $178.62 | Gamma | Nausea, vomiting, dacarbazine, Grades 1, 2 [12, 13] | $84.66 | $2.78 | $4485.98 | Gamma | Nausea, vomiting, dacarbazine, Grades 3, 4 [12–14] | $6665.84 | $4208.25 | $12075.84 | Gamma |
|
|